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Highlights 18 
 Histophilus somni is a respiratory pathogen of cattle. 19 
 Antimicrobial susceptibility testing was performed against commonly used antimicrobial 20 
agents.  21 
 Disc diffusion and minimum inhibitory concentration assays were mostly comparable. 22 
 Isolates from Australian cattle were almost completely susceptible bar, but one resistant 23 
isolate was identified.  24 
 Genotypic investigation detected a major cluster and clonal group of H. somni. 25 
 26 
 27 
 28 
29 
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 Abstract 30 
This study investigated antimicrobial resistance traits, clonal relationships and epidemiology 31 
of Histophilus somni isolated from clinically affected cattle in Queensland and New South Wales, 32 
Australia. Isolates (n = 53) were subjected to antimicrobial susceptibility testing against six 33 
antimicrobial agents (ceftiofur, enrofloxacin, florfenicol, tetracycline, tilmicosin and tulathromycin) 34 
using disc diffusion and minimum inhibitory concentration (MIC) assays. Clonal relationships were 35 
assessed using repetitive sequence PCR and descriptive epidemiological analysis was performed. 36 
The H. somni isolates appeared to be geographically clonal, with 27/53 (51%) isolates grouping in 37 
one cluster from one Australian state. On the basis of disc diffusion, 34/53 (64%) isolates were 38 
susceptible to all antimicrobial agents tested; there was intermediate susceptibility to tulathromycin 39 
in 12 isolates, tilmicosin in seven isolates and resistance to tilmicosin in one isolate. Using MIC, all 40 
but one isolate was susceptible to all antimicrobial agents tested; the non-susceptible isolate was 41 
resistant to tetracycline, but this MIC result could not be compared to disc diffusion, since there are 42 
no interpretative guidelines for disc diffusion for H. somni against tetracycline. In this study, there 43 
was little evidence of antimicrobial resistance in H. somni isolates from Australian cattle. Disc 44 
diffusion susceptibility testing results were comparable to MIC results for most antimicrobial agents 45 
tested; however, results for isolates with intermediate susceptibility or resistance to tilmicosin and 46 
tulathromycin on disc diffusion should be interpreted with caution in the absence of MIC results. 47 
Keywords: Histophilus somni; Bovine respiratory disease; Antimicrobial susceptibility; Disc 48 
diffusion; Minimum inhibitory concentration 49 
50 
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 Introduction 51 
Histophilus somni causes bovine respiratory disease (BRD) worldwide (Sandal and Inzana, 52 
2010). Although it is a commensal of the nasopharynx (Corbeil, 2007), H. somni can be an 53 
opportunistic pathogen of cattle, predominantly causing respiratory infections, but occasionally 54 
septicaemia, myocarditis, arthritis, abortion and other systemic infections (Sandal et al., 2007). 55 
 56 
BRD is the most economically important disease in beef cattle (Welsh et al., 2004), costing 57 
the Australian feedlot industry approximately AUD$40 million per year (Sackett et al., 2007). 58 
Antimicrobial agents including tetracycline, tilmicosin, florfenicol, tulathromycin, ceftiofur and 59 
enrofloxacin are used routinely to prevent and/or treat BRD (Welsh et al., 2004). A reliance on 60 
these drugs creates a selection pressure that may result in the emergence of drug-resistant 61 
microorganisms (Barton et al., 2003). Resistance is emerging amongst BRD pathogens, particularly 62 
to those antimicrobial agents from first generation classes (e.g. tetracycline) (Welsh et al., 2004; 63 
Portis et al., 2012). Moreover, antimicrobial resistance patterns vary according to bacterial species 64 
and geographical location (Hendriksen et al., 2008), meaning that local knowledge of 65 
susceptibilities is critical for the effective prevention and treatment of H. somni infections. 66 
 67 
The aim of this study was to determine the antimicrobial susceptibilities of H. somni against 68 
six antimicrobial agents commonly used to control and treat bovine bacterial respiratory pathogens 69 
via both disc diffusion and minimum inhibitory concentration (MIC) testing. Although MIC is 70 
considered to be the gold-standard test method in antimicrobial susceptibility determination 71 
(Andrews, 2001), disc diffusion is commonly used in veterinary diagnostic laboratories. An 72 
additional aim of this study was to assess associations between epidemiological factors (e.g. state of 73 
origin, production type, site of isolation), clonal relationships and antimicrobial susceptibility of H. 74 
somni cultured from Australian cattle. 75 
 76 
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  77 
Materials and methods 78 
Isolates 79 
Fifty-three H. somni isolates were obtained in 2012 from bovine samples that had been 80 
submitted to the Animal Disease Surveillance Laboratory, Toowoomba, Queensland or Elizabeth 81 
Macarthur Agricultural Institute, Menangle, New South Wales, Australia. Isolates were derived 82 
from cattle with clinical signs of respiratory disease (n = 51), thrombotic meningoencephalitis (n = 83 
1) or infertility (n = 1) and H. somni was considered to be the causal or a contributing pathogen. 84 
Isolates were recovered from lung samples (37/53, 70%), nasal swabs (6/53, 11%), brain swabs 85 
(3/53, 6%) and one each from a pleural swab, preputial swab and heart blood swab; the remaining 86 
four (8%) isolates were from unspecified sites. All isolates were confirmed as H. somni by clonal 87 
morphology, Gram stain and H. somni-specific PCR (Angen et al., 1998). The quality control strain 88 
H. somni ATCC 700025 was used for all testing. 89 
 90 
A clinical history, including location, breed, sex, age, production type and if the animal was 91 
introduced onto the property or homebred, was available for all cases, together with the results of 92 
serology or molecular testing for potential contributing pathogens, including infectious bovine 93 
rhinotracheitis virus (bovine herpesvirus type 1), bovine coronavirus and bovine pestivirus (bovine 94 
viral diarrhoea virus). 95 
 96 
Antimicrobial disc diffusion susceptibility 97 
Disc diffusion susceptibility testing was used to determine the antimicrobial susceptibility of 98 
H. somni isolates against ceftiofur (30 µg), enrofloxacin (5 µg), florfenicol (30 µg), tilmicosin (15 99 
µg) and tulathromycin (30 µg) according to Clinical and Laboratory Standards Institute (CLSI) 100 
guidelines (Clinical Laboratory Standards Institute, 2013). Since guidelines for tilmicosin were not 101 
available for H. somni, interpretation was based on guidelines for Mannheimia haemolytica 102 
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 (Blackall, 2007). Disc diffusion susceptibility testing was also performed for tetracycline (30 µg), 103 
although CLSI guidelines were not available for interpretation of these results. Tulathromycin discs 104 
were obtained from Becton Dickinson, while other antimicrobial discs were obtained from Oxoid. 105 
 106 
Minimum inhibitory concentration susceptibility testing 107 
The MICs of ceftiofur, enrofloxacin, florfenicol, tetracycline, and tilmicosin were 108 
determined according to CLSI guidelines for agar dilution (Clinical Laboratory Standards Institute, 109 
2013). The MICs of tulathromycin were determined for only 43 isolates using the same guidelines, 110 
since there were delays in obtaining tulathromycin antimicrobial powder and 10 isolates could not 111 
be revived for testing. Tulathromycin was obtained from Zoetis, while other antimicrobial powders 112 
were obtained from Sigma Aldrich. 113 
 114 
The MICs were determined as the lowest concentrations of antimicrobial agent in the plate 115 
that completely inhibited colony formation. All MICs were tested in duplicate independently on 116 
separate days. If duplicate tests were within one serial dilution of each other, they were accepted, 117 
and the MIC result was reported as the highest MIC. In all cases, duplicate MIC results were 118 
identical or within one serial dilution. 119 
 120 
Enterobacterial repetitive intergenic consensus PCR 121 
Clonality between the H. somni isolates was determined by enterobacterial repetitive 122 
intergenic consensus (ERIC) PCR (Versalovic et al., 1991). Banding patterns were analysed using 123 
GelComparII (Applied Maths) with a Dice coefficient of 0.28% and a tolerance of 2.8%. A cluster 124 
was defined as a group of isolates that shared ≥80% similarity in their ERIC-PCR patterns. Within 125 
each cluster, isolates with a similarity of >94% were considered to be a clonal group. Isolates were 126 
considered to be outliers if they were <70% similar. 127 
 128 
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 Epidemiological analysis 129 
Epidemiological analyses were performed with Epitools
1
. The effect of state (Queensland 130 
vs. New South Wales), production type (meat/feedlot vs. non-meat/feedlot) and sample site (lung 131 
vs. non-lung) for cluster 6 (the dominant cluster including 27/53 of all isolates) compared to isolates 132 
from other clusters was determined using the Fisher’s exact test. Other variables were not 133 
compared, since the total number of isolates in each category were <10. 134 
 135 
Results 136 
Antimicrobial susceptibility testing 137 
Using the disc diffusion method, 35/53 (66%) isolates were susceptible to all antimicrobial 138 
agents tested (Table 1). All isolates were susceptible to ceftiofur, enrofloxacin and florfenicol. 139 
Intermediate susceptibility against tulathromycin was exhibited by 12/53 (23%) isolates and against 140 
tilmicosin by 7/53 (13%) isolates; 2/53 (4%) isolates had intermediate susceptibility to both 141 
tulathromycin and tilmicosin, while 1/53 (2%) isolates exhibited resistance to tilmicosin. 142 
 143 
MICs, percentages of resistance to each antimicrobial agent, and MIC50 and MIC90 values 144 
are shown in Table 2. One of 53 (2%) isolates was resistant to tetracycline, with an MIC of 32 145 
µg/mL, while all other isolates were susceptible to all antimicrobial agents tested. 146 
 147 
There was complete agreement between the results of the disc diffusion and MIC methods 148 
for ceftiofur, enrofloxacin and florfenicol; all isolates were identified as susceptible with both 149 
methods. The isolate which exhibited tetracycline resistance in the MIC (32 µg/mL) had a 150 
corresponding disc diffusion of 22 mm (Fig. 1). 151 
 152 
                                                 
1
 See: http://epitools.ausvet.com.au (accessed 1 December 2014). 
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 Using CLSI breakpoints for M. haemolytica, all H. somni isolates were susceptible to 153 
tilmicosin on MIC (Fig. 1). Seven isolates had intermediate susceptibility to tilmicosin by disc 154 
diffusion, with zone diameters of 12-13 mm (intermediate breakpoints 11-13 mm); these isolates 155 
had MIC values of 2-8 µg/mL (susceptible breakpoint ≤8 µg/mL). The one resistant isolate had a 156 
zone diameter of 10 mm (resistant breakpoint ≤10 mm) and a corresponding MIC of 8 µg/mL. 157 
 158 
All 43 isolates tested were susceptible to tulathromycin on MIC testing (Fig. 1); 11/43 159 
(26%) isolates had intermediate susceptibility to tulathromycin by disc diffusion, all with a zone 160 
diameter of 16 mm (intermediate breakpoints 15-17 mm). These isolates had MIC values of 4-16 161 
µg/mL (susceptible breakpoint ≤16 µg/mL). 162 
 163 
Clonal relationships 164 
Using ERIC-PCR, 10 clusters were identified among the 53 H. somni isolates (Fig. 2). If 165 
five outlying clusters (clusters 1, 2, 9 and 10) were removed, the remaining isolates had a similarity 166 
level of >72% (Fig. 2). Twenty-seven of 52 (51%) isolates aligned with cluster 6; 15/27 (56%) 167 
isolates within cluster 6 belonged to clonal group 6.3. Cluster 8 included 7/53 (13%) isolates and 168 
cluster 4 included 6/53 (11%) isolates. The remaining eight isolates were distributed across three 169 
clusters, each with no more than four isolates. 170 
 171 
Epidemiology 172 
Thirty-six H. somni isolates originated from cattle in Queensland and 17 isolates originated 173 
from cattle in New South Wales (Table 3). Four clusters contained isolates from both Queensland 174 
and New South Wales (clusters 3, 5, 6 and 8). Cluster 6 consisted predominately of Queensland 175 
isolates (24/27, 89%); the proportion of isolates from Queensland in cluster 6 was significantly 176 
higher than the proportion of isolates from Queensland in all the other clusters combined (P < 0.01). 177 
Isolates in cluster 6 were cultured from samples from 17 different regions; clonal group 6.3 178 
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 contained only isolates from Queensland. Cluster 8 consisted mostly of Queensland isolates (6/7, 179 
86%). Clusters 1 and 4 contained isolates exclusively from New South Wales (2 and 6 isolates, 180 
respectively). The tetracycline resistant isolate belonged to cluster 8. Most isolates (38/53, 72%) 181 
were cultured from the lungs and most isolates (41/53, 77%) were cultured from feedlot/meat cattle 182 
(Table 3). Of the 38 isolates cultured from the lungs, four of these animals were also infected with a 183 
viral respiratory pathogen; 13 samples tested negative for one or more viral pathogens, whereas 21 184 
lung samples were not analysed). No patterns were apparent between cluster group and production 185 
type, sex, age, breed or introduction of an animal onto a property. 186 
 187 
Discussion 188 
Studies on BRD pathogens throughout the world, including Denmark (Aarestrup et al., 189 
2004), Australia (Blackall et al., 2007), North America (Portis et al., 2012), Japan (Katsuda et al., 190 
2009) and Canada (D’Amours et al., 2011), show that resistance to antimicrobial agents is 191 
increasing. The present study demonstrated that resistance against six antimicrobial agents in H. 192 
somni cultured from Australian cattle is either absent or extremely low. 193 
 194 
This study utilised two widely accepted methods, disc diffusion and MIC, for determining 195 
antimicrobial susceptibility in H. somni isolates. The results of the two tests for tilmicosin and 196 
tulathromycin were not comparable for all isolates, since a small number of isolates had 197 
intermediate susceptibility or resistant zone sizes on disc diffusion which were determined to be 198 
susceptible by the MIC method. Caution is needed in the interpretation of tilmicosin and 199 
tulathromycin disc diffusion results for isolates displaying intermediate susceptibility or resistance 200 
in the absence of MIC results. 201 
 202 
The finding that all isolates were susceptible to tilmicosin by MIC is supported by previous 203 
findings in another Australian study, in which all of 27 H. somni isolates tested were susceptible to 204 
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 tilmicosin (Blackall et al., 2007). A study in United States investigating tilmicosin susceptibility 205 
over time (1994-2002) showed that H. somni isolates were consistently susceptible (Welsh et al., 206 
2004). However, a later study from North America (2000-2009) identified a decrease in the 207 
susceptibility of H. somni to both tilmicosin and tulathromycin over time (Portis et al., 2012). One 208 
year prior to registration of tulathromycin in Northern America in 2004, 2-6% of BRD pathogens 209 
exhibited resistance and, by 2009, only 81% of H. somni remained susceptible (Portis et al., 2012). 210 
Therefore, continued surveillance should be a priority to detect any emergence of reduced 211 
susceptibility in H. somni. 212 
 213 
In our study, one H. somni isolate was resistant to tetracycline by the MIC method. 214 
Resistance to tetracycline has been demonstrated in H. somni in North America by Portis et al. 215 
(2012), who observed a decrease in tetracycline susceptibility from 83% of isolates in 2000 to 47% 216 
in 2009. Tetracycline resistance has not previously been reported in Australian isolates of H. somni; 217 
however, with the detection of a highly resistant isolate in the present study (isolated in 2012), 218 
tetracycline susceptibility in H. somni should be closely monitored. 219 
 220 
The 53 H. somni isolates formed 10 separate clusters, with the majority of isolates 221 
displaying high levels of similarity (Fig. 2). This supports previous studies suggesting there is 222 
limited genetic diversity in H. somni isolates and that the main mode of dispersal is clonal 223 
expansion (D’Amours et al., 2011). In our study, 51% of H. somni isolates belonged to cluster 6; 224 
within this cluster, clonal group 6.3 contained 56% of isolates. The isolates in cluster 6 were 225 
cultured from 1989 to 2011 and 85% were from cattle used for meat/feedlot production, but few 226 
conclusions can be drawn about the virulence potential of these isolates until further 227 
characterisation is performed. 228 
 229 
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 While this study was able to demonstrate low levels of resistance in H. somni isolates tested 230 
against a panel of commercially available antimicrobial agents, there are certain limitations to the 231 
study design. The sample size (n = 53) was too small to be able to draw definitive conclusions 232 
based on epidemiological data. Data were limited to histories provided at the time of submission. 233 
Isolates were from diagnostic samples and therefore were submitted at the discretion of veterinary 234 
practitioners, so may not be representative of H. somni in the wider population of cattle. 235 
 236 
Conclusions 237 
This study demonstrated that most isolates of H. somni from cattle in Queensland and New 238 
South Wales are susceptible to antimicrobial agents that are most frequently used to treat BRD. 239 
MIC and disc diffusion data were generally comparable, with the exception of tilmicosin and 240 
tulathromycin. Identification of a H. somni isolate with tetracycline resistance from 2012 highlights 241 
the importance of continued surveillance to ensure early detection of any emerging resistance. 242 
Genotypic investigation into clonal lineages identified a major cluster (cluster 6) and a clonal group 243 
(clone 6.3) within this cluster. 244 
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Figure legends 324 
 325 
Fig. 1. Comparison of disc diffusion and minimum inhibitory concentration (MIC) results of 326 
Australian isolates of Histophilus somni for (a) tetracycline, (b) tilmicosin and (c) tulathromycin. 327 
Solid line, resistant breakpoint; broken line, susceptible breakpoint. Isolates with a MIC value less 328 
than the lowest concentration tested have been given the value of the lowest concentration tested. 329 
Disc diffusion breakpoints for tetracycline are not available. Overlapping of data occurs at some 330 
points. 331 
 332 
Fig. 2. Dendrogram of enterobacterial repetitive intergenic consensus PCR fingerprint profiles of 53 333 
Histophilus somni isolates from cattle in Australia. QLD, Queensland; NSW, New South Wales. 334 
335 
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 Table 1 336 
Disc diffusion distribution and susceptibility zones of 53 Histophilus somni isolates. 337 
 338 
Antimicrobial agents 
Number of isolates (%) Disc diffusion zone sizes (mm) 
Susceptible Intermediate Resistant Median Range CLSI breakpoints 
Ceftiofur 53 (100%) 0 (0%) 0 (0%) 38 26 -48 R ≤17; S ≥21 
Enrofloxacin 53 (100%) 0 (0%) 0 (0%) 32 24- 42 R ≤16; S ≥21 
Florfenicol 53 (100%) 0 (0%) 0 (0%) 40 30-50 R ≤14; S ≥19 
Tilmicosin 45 (85%) 7 (13%) 1 (2%) 14 10-24 R ≤10; S ≥14 
Tulathromycin 41 (77%) 12 (23%) 0 (0%) 20 16-28 R ≤14; S ≥18 
Tetracycline NA
 
NA NA 28 22-36 NA 
 339 
S, susceptible; R, resistant; NA, not available; CLSI, Clinical and Laboratory Standards Institute.340 
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 Table 2 341 
Distribution of minimum inhibitory concentrations (MICs) of 53 Histophilus somni isolates. 342 
 343 
Antimicrobial agents 
Number of isolates with MIC (µg/mL)
 a
 
MIC50
 b
 MIC90
 c
 %R
 d
 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 
Ceftiofur 
e 
  50 2 1        0.12 0.12 0 
Tetracycline      18 34    1  2 2 1.9 
Enrofloxacin 9 37 7          0.06 0.12 0 
Tilmicosin      7 12 30 4    4 4 0 
Florfenicol   1 46 3 3       0.25 0.5 0 
Tulathromycin 
f
      2  15 20 6   8 16 0 
 344 
a
 Isolates with an MIC result as a range have been rounded up. 345 
b
 Lowest concentration of antimicrobial agent capable of inhibiting the growth of 50% of isolates. 346 
c
 Lowest concentration of antimicrobial agent capable of inhibiting the growth of 90% of isolates. 347 
d
 Percentage of resistance. 348 
e
 MICs to the right of the solid vertical lines indicate breakpoints for resistance; MICs to the left of the dotted vertical 349 
lines indicate breakpoints for susceptibility. 350 
f
 Only 43 H. somni could be revived for tulathromycin MIC testing.351 
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Table 3 352 
Distribution of isolates by category of epidemiological variables for all isolates, those from cluster 6 353 
and cluster 8. 354 
 355 
Variable Category 
Number and percentage of isolates 
(n = 53) 
Number cluster 6 
(n = 27) 
Number cluster 8 
(n =7 ) 
State Queensland
 
36 (67.9%) 24 (88.9%) 6 (85.7%) 
 New South Wales
 
17 (32.1%) 3
 
(11.1%) 1 (14.3%) 
Production Meat/Feedlot 41 (77.4%) 23
 
(85.2%) 6 (85.7%) 
 Dairy 5 (9.4%) 1 (3.7%) 1 (14.3%) 
 Unknown 7 (13.2%) 3 (11.1%) 0 (0%) 
Sample site Lung 38 (71.7%) 19 (70.4%) 6 (85.7%) 
 Brain 3 (5.7%) 2
 
(7.4%) 1 (14.3%) 
 Nasal 5 (9.4%) 1 (3.7%) 0 (0%) 
 Other 3 (5.7%) 3 (11.1%) 0 (0%) 
 Unknown 4 (7.5%) 2 (7.4%) 0 (0%) 
Year of isolation 1989-1994 4 (7.5%) 4
 
(14.8%) 0 (0%) 
 1995-2000 9 (17%) 6 (22.2%) 2 (28.6%) 
 2001-2005 9 (17%) 7 (25.9%) 2 (28.6%) 
 2006-2010 25 (47.2%) 6 (22.2%) 2 (28.6%) 
 2011-2012 2 (3.8%) 1 (3.7%) 1 (14.3%) 
 Unknown 4 (7.5%) 3 (11.1%) 0 (0%) 
Sex Male 13 (24.5%) 8 (29.6%) 1 (14.3%) 
 Female 11 (20.8%) 4 (14.8%) 2 (28.6%) 
 Unknown 29 (54.7%) 15 (55.6%) 4 (42.9%) 
Origin Introduced 23 (43.4%) 13 (48.2%) 4 (57.1%) 
 Homebred 7 (13.2%) 5 (18.5%) 0 (0%) 
 Unknown 23 (43.4%) 9 (33.3%) 3 (42.9%) 
Age (months) 0-6 12 (22.6%) 6 (22.2%) 3 (42.8%) 
 7-12 10 (18.9%) 5 (18.5%) 1 (14.3%) 
 13-18 15 (28.3%) 7 (26%) 2 (28.6%) 
 19-24 5 (9.4%) 3 (11.1%) 1 (14.3%) 
 Unknown 11 (20.8%) 6 (22.2%) 0 (0%) 
Other infections IBRV 
a 
1 (1.8%) 1 (3.7%) 0 (0%) 
 Coronavirus 2 (3.7%) 1 (3.7%) 0 (0%) 
 Pestivirus 1 (1.8%) 0 (0%) 1 (14.3%) 
 Negative 
b
 13 (24.5%) 9 (33.3%) 1 (14.3%) 
 Not tested 36 (67.9%) 16 (59.3%) 5 (71.4%) 
 356 
a
 Infectious bovine rhinotracheitis virus. 357 
b
 Tested for at least one virus but all results were negative.358 
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